Dr. Ianchulev is a Harvard-trained physician-executive, ophthalmic surgeon, inventor and serial entrepreneur, who has been at the forefront of medical innovation and products that have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year. While at Genentech, Dr. Ianchulev headed the ophthalmology clinical research group and directed the development and the FDA approval of Lucentis®, one of the most successful biotech innovations in the field of ophthalmology with more than $4B of annual sales.

As an inventor and developer, Dr. Ianchulev is behind many breakthrough technologies and venture-funded acquisitions–from the first ophthalmic intra-operative biometry device (Alcon, Inc.), the only FDA-approved suprachoroidal MIGS micro-stent (Alcon, Inc.), the first biologic stent technology in ophthalmology (Iantrek, Inc.), the original micro-interventional cataract fragmentation system (miLOOP, Zeiss Meditec) as well as the first microdose smart delivery system for topical therapeutics (Eyenovia, Inc.). Dr. Ianchulev’s robotics team at New York Eye and Ear and his pioneering work with Preceyes, Inc. lead to the introduction of micro-interventional robotics in ophthalmic surgery (Zeiss Meditec).

Dr. Ianchulev received both his medical degree (MD)and a Master of Public Health (MPH) degree from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. He is currently a Professor of Ophthalmology at New York Eye and Ear of Mount Sinai where he also directs the program for technology and innovation. Dr. Ianchulev is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field, which have been cited by more than 3,000 peer-reviewed publications. He also sits on a number of corporate and advisory boards.